Press Release Details
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.
Dr. Mazzo’s presentation will be delivered in-person and is scheduled for Wednesday, May 25, 2022 at 9:30 a.m. Eastern time. For more information on the conference and how to register, please contact your H.C. Wainwright representative or visit www.hcwevents.com/globalconference.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. We are and have been developing first-in-class autologous cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include: XOWNA® (CLBS16), the subject of both a recently completed positive Phase 2a study and an ongoing Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of a SAKIGAKE designation in Japan and eligible for early conditional approval for the treatment of critical limb ischemia (“CLI”) and Buerger’s disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”). No assurance can be given with respect to the future of these programs. For more information on the Company, please visit www.caladrius.com.
The Company recently announced that it has signed a definitive merger agreement with Cend Therapeutics, Inc. (www.cendrx.com). The merger is expected to close in the third quarter of 2022.
Caladrius Biosciences, Inc.
Vice President, Investor Relations and Corporate Communications